GlaxoSmithKline, AstraZeneca support API variation research

British drugmakers GlaxoSmithKline ($GSK) and AstraZeneca ($AZN) have put money into researching new technology to determine how processing affects APIs. Both companies have helped fund research at the University of Warwick in the U.K. into using nuclear magnetic resonance (NMR), which is usually used on liquids, to identify the different variations an API can take and so control for that, in-PharmaTechnologist reports. "This is very important for manufacturers because the interactions between organic molecules are quite weak. They can easily switch from one form to another, and this could provide different and adverse affect on patient," lead researcher Steven Brown tells the publication. NMR use could be a step forward over the "largely ineffective" X-ray diffraction method, the researchers say in a paper published in a scientific journal. A number of companies are looking for improvements in manufacturing, like continuous supply processing, to cut costs and make it more efficient and reliable. Story | More

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.